JRSSOTCServices-HospitalsFiscal year ends December 31
JRSIS HEALTH CARE Corp
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Dec 20, 2024
$0.01+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.10M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2023
Gross margin
14.0%
Operating margin
-5.4%−26.5 pts over 5 years
Net margin
-2.3%−9.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +101.4% | -54.1% | -34.4% | -2.3% | |
| Gross profit | +1742.9% | – | – | -17.0% | |
| Free cash flow | – | -39.9% | -38.6% | +5.9% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2018 | FY2023 | Trend |
|---|---|---|---|---|
| Return on equity | 49.6% | 14.7% | 82.6% | |
| Return on assets | 2.9% | 3.9% | -3.9% | |
| Current ratio | 0.96 | 1.67 | 0.80 | |
| Interest coverage | 0.9× | 5.3× | -3.3× | |
| Inventory turnover | 12.4× | – | 5.9× | |
| Capex to revenue | 60.1% | 11.5% | 0.0% | |
| Diluted shares | 18M | 20M | 77M |
Where the cash went
Fiscal 2019 to 2023, five years combined
Jrsis Health Care generated $33.00M from operations and spent $15.34M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$33.00M
Used
$15.34M
Capital expenditure$15.34M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2.3%
×Asset turnover1.65×
×Equity multiplier-21.37×
=Return on equity, FY202382.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -2.3% | 1.65× | -21.37× | 82.6% |
| FY2022 | -33.5% | 0.04× | 2.35× | -3.5% |
| FY2021 | 7.2% | 0.66× | 2.58× | 12.2% |
| FY2020 | 10.7% | 0.65× | 3.26× | 22.6% |
| FY2019 | 2.8% | 0.60× | 3.60× | 6.1% |
| FY2018 | 7.0% | 0.56× | 3.74× | 14.7% |
| FY2017 | 19.2% | 0.60× | 4.12× | 47.6% |
| FY2016 | 19.2% | 0.61× | 5.76× | 67.3% |
| FY2015 | 15.1% | 0.46× | 9.08× | 63.0% |
| FY2014 | 10.2% | 0.28× | 17.18× | 49.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
5of 8 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero-$80.91K
- Cash generatingOperating cash flow above zero$516.72K
- Return on assets improvedROA up on the prior year-0.8% → -4.0%
- Earnings backed by cashOperating cash flow above net income$516.72K vs -$80.91K
- Less leverageLong-term debt to assets fell– → 1.2%
- Better liquidityCurrent ratio rose0.79 → 0.80
- No dilutionShare count did not rise61M → 77M
- Gross margin improvedGross margin up on the prior year1.52% → 13.95%
- More efficientAsset turnover rose0.02 → 1.70